Bio Historical Cash Flow
| TECH Stock | USD 75.36 0.02 0.03% |
Analysis of Bio Techne cash flow over time is an excellent tool to project Bio Techne Corp future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Non Cash Items of 32.2 M or Capital Expenditures of 66 M as it is a great indicator of Bio Techne ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Bio Techne Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bio Techne Corp is a good buy for the upcoming year.
Bio |
About Bio Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Bio balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Bio's non-liquid assets can be easily converted into cash.
Bio Techne Cash Flow Chart
Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Capital Expenditures
Capital Expenditures are funds used by Bio Techne Corp to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Bio Techne operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Bio Techne Corp financial statement analysis. It represents the amount of money remaining after all of Bio Techne Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Most accounts from Bio Techne's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Bio Techne Corp current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. As of now, Bio Techne's Other Non Cash Items is decreasing as compared to previous years. The Bio Techne's current Capital Expenditures is estimated to increase to about 66 M, while Sale Purchase Of Stock is forecasted to increase to (76 M).
Bio Techne cash flow statement Correlations
Click cells to compare fundamentals
Bio Techne Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio Techne cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | (50.1M) | (43.2M) | (161.0M) | (19.6M) | (80.0M) | (76.0M) | |
| Change To Inventory | (14.9M) | (7.1M) | (32.0M) | 400K | (14.2M) | (13.5M) | |
| Change In Cash | 45.7M | 52.5M | (26.5M) | 8.0M | (28.8M) | (27.3M) | |
| Free Cash Flow | 153.5M | 307.9M | 280.4M | 216.1M | 236.1M | 247.9M | |
| Change In Working Capital | (5.2M) | 29.3M | (69.5M) | (48.2M) | (10.1M) | (9.6M) | |
| Begin Period Cash Flow | 100.9M | 146.6M | 199.1M | 172.6M | 180.6M | 189.6M | |
| Other Cashflows From Financing Activities | (7.3M) | (19.3M) | 143.8M | 92.5M | 39.1M | 26.8M | |
| Depreciation | 82.7M | 87.7M | 101.1M | 107.2M | 111.7M | 117.3M | |
| Other Non Cash Items | (147.1M) | 74.0M | (18.4M) | (99.8M) | 30.7M | 32.2M | |
| Capital Expenditures | 51.7M | 44.3M | 44.9M | 38.2M | 62.9M | 66.0M | |
| Total Cash From Operating Activities | 205.2M | 352.2M | 325.3M | 254.4M | 299.0M | 313.9M | |
| Net Income | 229.3M | 139.6M | 263.1M | 285.4M | 168.1M | 89.4M | |
| Total Cash From Financing Activities | (183.8M) | (62.6M) | (242.9M) | 22.6M | (122.4M) | (116.3M) | |
| End Period Cash Flow | 146.6M | 199.1M | 172.6M | 180.6M | 151.8M | 91.7M | |
| Stock Based Compensation | 32.4M | 49.0M | 42.2M | 39.2M | 38.0M | 39.9M | |
| Change To Netincome | 43.8M | 94.7M | (47.8M) | (37.2M) | (42.8M) | (40.6M) | |
| Total Cashflows From Investing Activities | 27.1M | (243.5M) | (96.9M) | (265.6M) | (239.1M) | (227.1M) | |
| Dividends Paid | 48.9M | 49.6M | 50.2M | 50.3M | 50.4M | 49.8M | |
| Change To Account Receivables | 6.6M | (15.5M) | (57.6M) | (20.9M) | (20.5M) | (21.6M) | |
| Investments | 76.9M | (243.5M) | (96.9M) | (265.6M) | (203.0M) | (192.9M) | |
| Change Receivables | 6.6M | (15.5M) | (57.6M) | (20.9M) | (18.8M) | (19.7M) | |
| Cash And Cash Equivalents Changes | 48.5M | 46.1M | (14.4M) | 11.4M | 13.1M | 8.3M | |
| Cash Flows Other Operating | (148.0M) | 72.2M | (39.1M) | (15.1M) | (13.6M) | (12.9M) | |
| Other Cashflows From Investing Activities | 1.9M | (225.9M) | (51.9M) | (28.0M) | (32.2M) | (33.8M) | |
| Change To Liabilities | 5.7M | 19.1M | 12.7M | (35.0M) | (31.5M) | (29.9M) | |
| Net Borrowings | (148.5M) | (15.5M) | (85.5M) | 94M | 84.6M | 88.8M | |
| Change To Operating Activities | (53K) | 19.4M | 4.7M | (29.1M) | (26.2M) | (24.9M) |
Currently Active Assets on Macroaxis
When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.32) | Dividend Share 0.32 | Earnings Share 0.95 | Revenue Per Share 7.424 | Quarterly Revenue Growth 0.045 |
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.